PROVIDENCE – MindImmune Therapeutics, a company developing innovative treatments for Alzheimer’s and other neurodegenerative diseases, announced this week that it has raised $30 million in extended Series A funding and appointed Isaac Stoner as CEO. The life sciences company, which launched at the University of Rhode Island in 2016, targets neuroinflammation as a cause for
Already a Subscriber? Log in
To Continue Reading This Article
Become a Providence Business News subscriber and get immediate access to all of our premier content and much more.Learn More and Become a Subscriber
- Critical RI business news and analysis updated daily.
- 1 year of print (26 issues).
- Unlimited access to all subscriber only content on our website, on any device.
- Free email alerts.
- Annual Book of Lists Print Edition.
- All special issues produced during subscription term.
Click Here to purchase a paywall bypass link for this article
PBN Branded Content
Beyond Cash Donations: How New Forms of Giving Are Transforming Not-for-Profit Accounting
Evolving Funding Landscape for Not-for-Profits Not-for-profit organizations are being asked to do more with less,…
Learn More
